| Age, years |
57.9 |
14.1 |
35.8 |
14.2 |
54.8 |
12.5 |
49.4 |
15.4 |
| Female, % |
62.5% |
40 |
92.7% |
109 |
78.7% |
85 |
68.0% |
17 |
| Race/Ethnicity, % |
|
|
|
|
|
|
|
|
| White |
79.7% |
51 |
53.4% |
62 |
90.7% |
98 |
68.0% |
17 |
| Black |
1.6% |
1 |
18.1% |
21 |
0.9% |
1 |
8.0% |
2 |
| Asian |
6.2% |
4 |
14.7% |
17 |
2.8% |
3 |
16.0% |
4 |
| Aboriginal |
1.6% |
1 |
0.9% |
1 |
1.9% |
2 |
0% |
0 |
| Others |
10.9% |
7 |
12.9% |
15 |
3.7% |
4 |
8.0% |
2 |
| Education, % |
|
|
|
|
|
|
|
|
| High school or less |
32.8% |
21 |
28.4% |
33 |
48.1% |
52 |
52.0% |
13 |
| > High school |
67.2% |
43 |
71.6% |
83 |
51.9% |
56 |
48.0% |
12 |
| Full- or part-time employment, % |
56.3% |
36 |
- |
- |
50.9% |
55 |
32.0% |
8 |
| Smoking, % |
|
|
|
|
|
|
|
|
| Never |
51.5% |
33 |
60.7% |
71 |
45.4% |
49 |
68.0% |
17 |
| Current |
9.4% |
6 |
14.5% |
17 |
12.0% |
13 |
0% |
0 |
| Past |
39.1% |
25 |
24.8% |
29 |
42.6% |
46 |
32.0% |
8 |
| Disease variables |
|
|
|
|
|
|
|
|
| Disease duration, years |
0.5 |
0.3 |
0.4 |
0.3 |
0.7 |
0.2 |
0.5 |
0.3 |
| Inflammatory arthritis, % |
100.0% |
64 |
70.3% |
83 |
26.9% |
29 |
32.0% |
8 |
| Interstitial lung disease, % |
0 |
0 |
2.5% |
3 |
30.6% |
33 |
68.0% |
17 |
| Myositis, % |
0 |
0 |
3.2% |
3 |
13.9% |
15 |
100.0% |
25 |
| Raynaud's phenomenon, % |
3.1% |
2 |
20.5% |
24 |
89.8% |
97 |
20.0% |
5 |
| Sicca, % |
19.1% |
12 |
- |
- |
40.2% |
43 |
44.0% |
11 |
| Global disease activity (range 0–10) |
4.2 |
2.3 |
2.5 |
2.6 |
4.7 |
2.8 |
4.8 |
1.9 |
| Global disease damage (range 0–10) |
- |
- |
0.5 |
1.2 |
4.0 |
2.6 |
1.4 |
1.6 |
| Medications variables, currently |
|
|
|
|
|
|
|
|
| Corticosteroids |
23.4% |
15 |
61.1% |
44 |
27.3% |
27 |
85.0% |
17 |
| DMARDS |
37.5% |
24 |
91.2% |
104 |
26.5% |
27 |
85.7% |
12 |
| Outcome variables |
|
|
|
|
|
|
|
|
| Physical component summary score* |
37.1 |
13.3 |
38.9 |
12.2 |
35.0 |
13.6 |
28.0 |
15.4 |
| Mental component summary score* |
45.0 |
13.3 |
40.1 |
14.3 |
44.4 |
14.7 |
33.6 |
18.7 |
